News | August 25, 2008

FRANCIS Clinical Trial to Measure Impact of Varespladib on ACS Patients

August 26, 2008 - Anthera Pharmaceuticals Inc. yesterday announced the initiation of the FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression) clinical trial to examine the impact of varespladib when administered to patients within 96 hours of an acute coronary syndrome (ACS) event.
Designed to assess the impact of oral varespladib on known biological markers of cardiovascular risk, the FRANCIS trial will enroll up to 500 patients who will be treated for a minimum of six months. The study will be conducted at sites in North America and Europe to provide insight into the prevention of secondary Major Adverse Cardiovascular Events (MACE) over the duration of the trial. In this study, MACE is defined as a composite endpoint consisting of cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, unstable angina and a subset of revascularization following the initial event.
During the course of the study, patients will receive therapeutic standard of care in addition to high dose Lipitor (atorvastatin). In previous clinical trials, according to Anthera, varespladib, a potent and highly selective inhibitor of secretory phospholipase A2 (sPLA2), has demonstrated marked improvements in independent markers of cardiovascular risk including, a near complete suppression of the target enzyme sPLA2, a clinically meaningful and statistically significant reduction in "bad" LDL cholesterol, and a reduction in C-reactive protein a known marker of inflammation.
"Based upon the success of varespladib in two previous Phase II clinical trials in patients with cardiovascular disease in which it demonstrated lipid-lowering and anti-inflammatory benefits, we look forward to further evaluating the impact of varespladib on the hyper-inflammatory state presented by ACS patients," said James Pennington, M.D., executive vice president and chief medical officer of Anthera Pharmaceuticals, Inc.
For more information: www.anthera.com/

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
New Study Focuses on Protein Responsible For Increased Heart Disease Risk
News | Cardiac Diagnostics| August 03, 2017
August 3, 2017 — A study to reduce the strongest inherited...
Overlay Init